Type-I MAGE promotes cancer cell survival in various ways: (1) by interacting with ubiquitin system to promote degradation of tumor suppressor proteins (e.g., p53, AMPKα1, ZNF382), (2) by inhibiting cyclin degradation, (3) by acting as transcription regulators [548], (4) by repressing, in the case of other CTAGs (PRAME), retinoic acid signaling thereby inhibiting differentiation [549]. Here, TP53 is linked to cancer.